9474780 May 13, 2036 — Yes Yes U-4374 MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS — 11357820 Jun 14, 2039 — — Yes — — 12295987 Dec 30, 2041 — — — U-4192 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE — 12295987 Dec 30, 2041 — — — U-4193 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE — 12343382 Jul 22, 2039 — — — U-4231 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS — 12343382 Jul 22, 2039 — — — U-4232 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS — 12343382 Jul 22, 2039 — — — U-4400 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS — 12343382 Jul 22, 2039 — — — U-4401 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS — 12343382 Jul 22, 2039 — — — U-4229 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS — 12343382 Jul 22, 2039 — — — U-4230 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS — 12453755 Jun 14, 2039 — — — U-4375 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0 – 7.0 MG/ML PHENOL — 12453755 Jun 14, 2039 — — — U-4376 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4377 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4378 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1 – 3 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4379 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67 – 2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4380 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 – 9.5 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4381 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4382 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0 – 9.0 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4383 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4384 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL — 12453755 Jun 14, 2039 — — — U-4385 IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL — 12453755 Jun 14, 2039 — — — U-4386 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5 — 12453756 Jun 14, 2039 — — Yes — — 12616740 Jul 22, 2039 — — — U-4500 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG — 12616740 Jul 22, 2039 — — — U-4501 TREATMENT OF TYPE 2 DIABETES BY SUBCUTANEOUSLY ADMINISTERING WITH METFORMIN A ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE DOSE IN INCREMENTS OF 2.5 MG FOR 4 WEEKS EACH TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG — 12616740 Jul 22, 2039 — — — U-4502 IMPROVING GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT BY SUBCUTANEOUSLY ADMINISTERING TIRZEPATIDE AT 2.5 MG ONCE WEEKLY FOR AT LEAST FOUR WEEKS AND INCREASING THE DOSE IN 2.5 INCREMENTS FOR 4 WEEKS EACH TO 5 MG, 7.5 MG, 10 MG, OR 12.5 MG ONCE WEEKLY — 12629404 Jun 14, 2039 — — Yes U-4534 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 6.2 - 9.5 MG/ML NACL, AND DIBASIC SODIUM PHOSPHATE WHEREIN THE COMPOSITION IS FREE FROM PRESERVATIVE — 12629404 Jun 14, 2039 — — Yes U-4533 A METHOD FOR TREATING TYPE-2 DIABETES BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE AND ABOUT 6.2 - 9.5 MG/ML NACL, WHEREIN THE COMPOSITION HAS A PH OF ABOUT 6.5 - 7.5 AND IS FREE FROM PRESERVATIVE —